Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc. has announced that the FDA has granted Breakthrough Therapy Designation (BTD) to its psychedelic molecule CYB003, potentially fast-tracking its development as a novel treatment for Major Depressive Disorder (MDD). Furthermore, CYB003 has shown promising results in a Phase 2 trial, with a substantial number of patients experiencing remission after treatment. These advancements signal a major step toward offering new hope for individuals suffering from depression.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
